The molecular principle of RIPTAC technology—From induced proximity to the precise anti-cancer logic of "occupational hijacking"

Following the wave of drug development driven by "induced proximity" in targeted protein degradation (PROTAC) technology, a new type of bifunctional molecule—RIPTAC (Regulated Induced Proximity Targeting Chimera)—has emerged with a unique anti-cancer logic, capturing industry attention. In 2025, Halda Therapeutics' first RIPTAC molecule, HLD-0915, completed dosing in its first patient and reported positive clinical data; in November of the same year, Johnson & Johnson acquired Halda for $3.05 billion, marking the largest transaction in the induced proximity field. Why has RIPTAC garnered such significant industry investment? How does its technical principle fundamentally differ from traditional protein degradation? This article systematically analyzes the molecular design logic and mechanism of action of RIPTAC, starting from the chemical basis of induced proximity.

Chemically Induced Proximity (CIP) is a technological paradigm that uses small molecules to bring two proteins into close proximity and induce specific biological effects. Unlike traditional small-molecule inhibitors, which rely on an "occupancy-driven" model of continuous target occupation, CIP follows an "event-driven" model—small molecules need only catalytically induce protein proximity to trigger downstream events.

PROTAC is the first representative of the CIP field to achieve clinical breakthroughs: bifunctional molecules bind the target protein at one end and an E3 ubiquitin ligase at the other, inducing the degradation of the target protein by the ubiquitin-proteasome system. RIPTAC also adopts a bifunctional molecular design but replaces the "E3 ubiquitin ligase" effector with a "pan-essential effector protein (EP) critical for cell survival." This substitution shifts the outcome from "degrading the target protein" to "functionally blocking the effector protein"—a fundamental paradigm shift.

As a heterobifunctional small molecule, RIPTAC consists of three covalently linked structural units: a targeting protein ligand (TP ligand), an essential protein ligand (EP ligand), and a chemical linker connecting the two.

The TP ligand is responsible for recognizing and binding to target proteins that are highly expressed specifically in tumor cells—these can be oncogenic driver proteins (e.g., ALK, BCL6), tumor-associated antigens (e.g., androgen receptor AR), or tumor-specific proteins generated by mutations (e.g., p53-Y220C mutant). The EP ligand binds to a pan-essential protein critical for the survival of all cells (e.g., BRD4, CDK, or other transcription regulators or cell cycle proteins).

When RIPTAC enters a cell co-expressing TP and EP, the two ligands bind their respective target proteins, bringing TP and EP into close proximity through the physical connection of the linker, forming a stable TP:RIPTAC:EP ternary complex. The key to this process lies in positive cooperativity—the binding of TP to RIPTAC enhances RIPTAC's affinity for EP, and vice versa, making the formation of the ternary complex thermodynamically highly favorable. Since TP is not expressed or expressed at extremely low levels in normal cells, the ternary complex cannot form, and RIPTAC cannot exert its effects in normal cells.

The cell-killing mechanism of RIPTAC is described by Halda as "hold and kill." Its core logic operates on two levels.

First—"Hold": RIPTAC physically captures EP near TP through the formation of the ternary complex. This capture is not transient but sustained through the stabilization of the ternary complex. Since EP is critical for cell survival, its "locking" in a non-functional state directly threatens cell viability.

Second—"Kill": After EP's function is blocked, the cell loses essential activities required for survival. Taking BRD4 as an example, BRD4 is a core transcription regulator, and its functional loss leads to the termination of downstream pro-survival gene transcription, ultimately inducing tumor cell apoptosis. Notably, RIPTAC's killing does not depend on the oncogenic function of the target protein—TP serves only as an "anchor" to provide tumor selectivity. Even if TP itself lacks enzymatic activity or a druggable pocket, RIPTAC can still function. This feature enables RIPTAC to target "undruggable" targets that traditional small-molecule inhibitors cannot address.

The tumor selectivity of RIPTAC stems from a simple logic: the ternary complex can form and function only in cells where both TP and EP are co-expressed.

The key to this mechanism lies in co-expression dependency. High expression of TP in tumor cells is a necessary condition for RIPTAC to exert its effects. When TP is absent or expressed at very low levels, the ternary complex cannot form, and EP remains free to perform its essential functions normally. This "dual-lock" mechanism ensures highly selective killing of tumor cells while protecting normal tissues from damage.

A 2025 doctoral dissertation from Yale University systematically studied the selectivity principle of RIPTAC. Researchers constructed the RIPTAC molecule HLDA-6623 using BCL6 as the target protein and BRD4 as the effector protein. The study found that HLDA-6623 exhibited enhanced cytotoxicity in cells expressing wild-type BCL6 and cells expressing DNA-binding mutant BCL6, and this cytotoxicity was not mediated by transcriptional reprogramming (TCIP mechanism) but directly driven by RIPTAC's unique ternary complex formation mechanism. This finding provides direct evidence for RIPTAC's "occupational hijacking" rather than "signal regulation" mode of action.

Although RIPTAC and PROTAC share the structural skeleton of heterobifunctional molecules, they differ fundamentally in their mechanisms of action:

The catalytic nature of PROTAC allows it to be recycled, whereas RIPTAC requires sustained maintenance of the ternary complex state to exert its effects. However, RIPTAC does not rely on the ubiquitin-proteasome system (UPS), avoiding limitations imposed by tissue-specific E3 ligase distribution and target protein degradation efficiency. More importantly, RIPTAC does not require the target protein to have enzymatic activity or a druggable pocket—the target protein need only serve as an "anchor" to provide tumor selectivity. This characteristic enables RIPTAC to target protein types that are difficult for PROTAC to address, such as scaffold or structural proteins lacking degradability.

The core principle of RIPTAC technology can be summarized as: using heterobifunctional small molecules to induce the formation of a stable ternary complex between a target protein and a pan-essential effector protein in tumor cells, achieving tumor-selective killing by "occupational hijacking" to block the essential functions of the effector protein. This mechanism does not rely on target protein degradation, the UPS system, or the target protein's enzymatic activity—it only requires the target protein to be highly expressed in tumor cells. It is this unique logic of "functional blockade rather than protein degradation" that sets RIPTAC apart from the induced proximity paradigm pioneered by PROTAC, establishing it as a novel anti-cancer strategy with broad target applicability.

```